Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
95227 trials found · Page 160 of 4762
-
New shot could tame lupus flares
Disease control Recruiting nowThis was a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study. The primary objective was to evaluate the efficacy of SG301 SC injection in participants with Systemic Lupus Erythematosus (SLE) based on the Systemic Lupus Erythematosus Responder Index …
Phase: PHASE2 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated May 06, 2026 16:01 UTC
-
Wrist gadget could spot strokes before It's too late
Knowledge-focused Recruiting nowThe Neuralert monitoring system, a non-invasive device worn on each wrist, is designed to provide continuous monitoring and expedited recognition of stroke by identifying asymmetry in the extremities, facilitating patient treatment and improving outcomes. This study is designed t…
Phase: NA • Sponsor: Neuralert Technologies LLC • Aim: Knowledge-focused
Last updated May 16, 2026 17:58 UTC
-
New drug duo takes on hard-to-treat blood cancer
Disease control Recruiting nowThis study is researching a drug called REGN17372 used with another drug called linvoseltamab (each individually called "study drug" or "study drugs" when combined) in participants with relapsed (when a tumor comes back) or refractory (when a tumor does not respond to treatment) …
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 16, 2026 17:57 UTC
-
New hope for lung injury patients: pirfenidone trial targets radiation and immune damage
Disease control Recruiting nowRadiation-induced lung injury (RILI) is one of the most common thoracic-radiotherapy complications, with an incidence as high as 31.4 %. Multiple studies have shown that RILI can adversely affect patient prognosis by disrupting treatment schedules. Moreover, the widespread clinic…
Phase: PHASE2, PHASE3 • Sponsor: Beijing Continent Pharmaceutical Co, Ltd. • Aim: Disease control
Last updated May 11, 2026 20:54 UTC
-
New combo pill aims to melt fat, not muscle, in seniors
Disease control Recruiting nowThe primary objective of this study is to assess the effect of enobosarm on total body weight
Phase: PHASE2 • Sponsor: Veru Inc. • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New test could tailor breast cancer therapy for better results
Disease control Recruiting nowThis is an open-label phase 2 study to evaluate the pCR rate in patients diagnosed with HER2 positive breast cancer treated on an adaptive clinical trial design. Tumors will undergo testing using a novel molecular phosphoprotein-based biomarker assay, HER2 Activation Response Pr…
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated May 16, 2026 17:53 UTC
-
New pill could tame severe ulcerative colitis Flare-Ups
Disease control Recruiting nowThe main purpose of this study is to evaluate the safety and effectiveness of LY4268989 when compared to placebo in adult participants with moderately to severely active ulcerative colitis (UC). The study drug will be administered orally. The study will last up to approximately …
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New combo aims to wipe out breast cancer before surgery
Disease control Not yet recruitingTo evaluate the efficacy and safety of Serplulimab in combination with Trastuzumab Restuzumab for the neoadjuvant treatment of triple-negative breast cancer, aiming to provide evidence for optimizing the strategy of combining immunotherapy with ADC drugs in the neoadjuvant settin…
Phase: PHASE2 • Sponsor: Xijing Hospital • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New hope for Hard-to-Treat cancers: targeted combo therapy enters Mid-Stage trial
Disease control Not yet recruitingA Phase II study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of IBI343 in combination therapy for patients with advanced malignant solid tumors.To evaluate the efficacy and safety of IBI343 in combination therapy for patients with advanced malignant solid…
Phase: PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated May 06, 2026 16:13 UTC
-
New drug combo aims to shrink advanced ovarian, cervical, and endometrial tumors
Disease control Not yet recruitingThis is an open-label, multicenter, Phase II clinical study to evaluate the efficacy and safety of SKB518 as monotherapy or combination therapy in patients with advanced gynecological malignancies. This study will include 5 cohorts: SKB518 as monotherapy in advanced ovarian canc…
Phase: PHASE2 • Sponsor: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. • Aim: Disease control
Last updated May 04, 2026 16:18 UTC
-
Laser zaps brain tumors in kids: new hope for recurrent Low-Grade glioma
Disease control Recruiting nowThis study aims to evaluate the efficacy of Laser Interstitial Thermal Therapy (LITT) in treating recurrent or progressive, low-grade gliomas (LGG) in pediatric, adolescent and young adult patients.
Phase: NA • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New combo therapy aims to wipe out early TNBC before surgery
Disease control Not yet recruitingCamrelizumab + Chemoradiotherapy for Early TNBC Sponsor/Leading Center: Tianjin Medical University Cancer Institute and Hospital Study Type: Single-arm, single-center, Phase Ⅱ clinical study Planned Enrollment: 43 patients Eligible Population 18-75-year-old female patients with n…
Phase: NA • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 16, 2026 17:57 UTC
-
New drug aims to keep insulin flowing in early type 1 diabetes
Disease control Recruiting nowThis Phase 2 study is a 2-arm, multi-center, double-masked (masking of the participant, care provider and investigator), placebo-controlled, 2:1 randomized trial design in new onset T1D participants (within 100 days of diagnosis). Participants will be administered rezpegaldesleuk…
Phase: PHASE2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
AI-Powered wearables could predict heart attacks before they happen
Knowledge-focused Not yet recruitingAcute myocardial infarction (AMI), as the leading cause of death among cardiovascular diseases, has its diagnosis and treatment efficiency directly affecting survival. Although the current diagnosis and treatment system has significantly improved in-hospital outcomes, delays in s…
Sponsor: Beijing Anzhen Hospital • Aim: Knowledge-focused
Last updated May 16, 2026 17:53 UTC
-
Double dose hope: new stroke study aims to save more brains
Disease control Recruiting nowWhile intravenous thrombolysis (IVT) within 4.5 hours is the standard medical reperfusion therapy, its efficacy is limited, particularly for large or medium vessel occlusions (LVO/MeVO), with low recanalization rates for IVT with rt-PA. The newer thrombolytic agent, tenecteplase …
Phase: PHASE2 • Sponsor: General Hospital of Shenyang Military Region • Aim: Disease control
Last updated May 04, 2026 16:18 UTC
-
New mRNA HIV vaccines enter human testing – could they teach the body to neutralize the virus?
⭐️ VACCINE ⭐️ Recruiting nowThis is a phase 1, multicenter, open-label, dose escalation, first-in-human (FIH) trial to evaluate the safety and immunogenicity of DV201P-RNA and DV202B1-RNA, immunogens designed to induce HIV-1 envelope (Env) V2 apex-specific broadly neutralizing antibodies (V2 apex bnAbs). Bo…
Phase: PHASE1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: ⭐️ VACCINE ⭐️
Last updated May 16, 2026 17:55 UTC
-
New combo therapy aims to shrink tough head and neck cancers
Disease control ENROLLING_BY_INVITATIONThis research study is for people who have head and neck cancer that has come back or spread to other places in the body.
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 16, 2026 17:56 UTC
-
New cocktail therapy shows promise for tough liver tumors
Disease control Recruiting nowThe goal of this clinical trial is to evaluate the safety, tolerability, and preliminary efficacy of a combination therapy involving TACE, sintilimab, bevacizumab, and ipilimumab N01 for the treatment of advanced hepatocellular carcinoma (HCC). It also aims to explore the potenti…
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated May 01, 2026 16:01 UTC
-
Bladder cancer breakthrough? old drug shows new promise in preventing recurrence
Prevention Recruiting nowLow grade non-muscle-invasive bladder cancer (NMIBC) often recurs after treatment, requiring repeated surgeries, especially in older patients. These recurrences can cause complications, reduce quality of life, and increase healthcare costs. Currently, there is no well-tolerated p…
Phase: PHASE2 • Sponsor: Paul Toren • Aim: Prevention
Last updated May 15, 2026 11:57 UTC
-
New hope for bile duct cancer: targeted drug trial launches
Disease control Recruiting nowThis is a multicenter, Phase 2 clinical trial to evaluate the efficacy and safety, PK and immunogenicity of SHR-A1904 in patients with advanced or metastatic biliary tract cancer (BTC). Patients will treat with SHR-A1904 until unacceptable toxicity or disease progression.
Phase: PHASE2 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated May 11, 2026 20:41 UTC